Share on StockTwits

Endocyte (NASDAQ:ECYT) announced its earnings results on Monday. The company reported ($0.08) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.14) by $0.06, reports. The company had revenue of $17.30 million for the quarter, compared to the consensus estimate of $15.90 million.

A number of research firms have recently commented on ECYT. Analysts at Zacks upgraded shares of Endocyte from a “neutral” rating to an “outperform” rating in a research note on Wednesday, January 15th. They now have a $14.40 price target on the stock. Analysts at Piper Jaffray initiated coverage on shares of Endocyte in a research note on Monday, December 2nd. They set an “overweight” rating and a $17.00 price target on the stock. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. Endocyte presently has an average rating of “Buy” and an average price target of $19.24.

Endocyte (NASDAQ:ECYT) opened at 14.94 on Monday. Endocyte has a 1-year low of $8.18 and a 1-year high of $19.00. The stock has a 50-day moving average of $12. and a 200-day moving average of $12.6. The company’s market cap is $540.0 million.

In other Endocyte news, Insider Philip Low sold 6,000 shares of Endocyte stock on the open market in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $15.00, for a total transaction of $90,000.00. Following the completion of the transaction, the insider now directly owns 200,819 shares of the company’s stock, valued at approximately $3,012,285. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Endocyte, Inc (NASDAQ:ECYT) is a biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.